Public disclosures

Agarwal Arjun

Company insiders · Senior Vice President, Finance · Oruka Therapeutics, Inc.

Advertisement
FollowLatest SEC filingSEC filer historyProfile details as reported on 2026-11-13.Following & alerts
Reported transaction lines
10
Buy lines
0
Sell lines
6

Filing activity by month

Original filing lines in up to 12 months with activity.

  • 2026-1110

Frequently disclosed stocks

Disclosure history

More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSource
Agarwal Arjun

Senior Vice President, Finance · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Employee Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 55417 · The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.

2026-11-122026-11-13

1,458 shares/units

SEC 4
Agarwal Arjun

Senior Vice President, Finance · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Employee Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 67834 · The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.

2026-11-122026-11-13

8,542 shares/units

SEC 4
Agarwal Arjun

Senior Vice President, Finance · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 14219 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

2026-11-122026-11-13

≈ $10,700.00

100 shares/units

SEC 4
Agarwal Arjun

Senior Vice President, Finance · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 14319 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.82 to $106.52, inclusive.

2026-11-122026-11-13

≈ $101,716.51

958 shares/units

SEC 4
Agarwal Arjun

Senior Vice President, Finance · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 15277 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.82 to $105.81, inclusive.

2026-11-122026-11-13

≈ $720,329.87

6,842 shares/units

SEC 4
Agarwal Arjun

Senior Vice President, Finance · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 22119 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.75 to $104.65, inclusive.

2026-11-122026-11-13

≈ $83,295.91

799 shares/units

SEC 4
Agarwal Arjun

Senior Vice President, Finance · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 22918 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.75 to $103.70, inclusive.

2026-11-122026-11-13

≈ $82,627.64

801 shares/units

SEC 4
Agarwal Arjun

Senior Vice President, Finance · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 23719 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.28 to $102.22, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), and (6) to this Form 4.

2026-11-122026-11-13

≈ $50,987.90

500 shares/units

SEC 4
Agarwal Arjun

Senior Vice President, Finance · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 24219

2026-11-122026-11-13

1,458 shares/units

SEC 4
Agarwal Arjun

Senior Vice President, Finance · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 22761

2026-11-122026-11-13

8,542 shares/units

SEC 4

Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.

Advertisement